Which antipsychotic is approved for the treatment of Major Depressive Disorder (MDD)?

Quetiapine is approved for the treatment of Major Depressive Disorder (MDD) as an adjunct therapy. This means it can be used alongside traditional antidepressants to enhance their effectiveness in treating the depressive symptoms associated with MDD. Quetiapine has been shown to alleviate depressive symptoms and has a favorable side effect profile compared to some other antipsychotics, making it a viable option within a broader treatment strategy for individuals with MDD.

The other choices are either not primarily used for treating MDD or have different primary indications. Lithium is primarily utilized as a mood stabilizer, especially in bipolar disorder, rather than for MDD alone. Haloperidol is primarily an antipsychotic used for managing acute psychosis and has limited application in depressive disorders. Carbamazepine is generally used as an anticonvulsant and mood stabilizer, but it is not specifically approved for treating MDD. Thus, Quetiapine stands out as a relevant choice for addressing MDD symptoms, demonstrating its role within the broader treatment landscape for this condition.